The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
